---
import { biomarkers } from '@/assets/biomarkers'
import BlockQuote from "@/components/BlockQuote.astro";
import SEOMeta from "@/components/meta-data-helpers/SEOMeta.astro";
import TopPageBanner from "@/components/TopPageBanner-1.astro";
import Layout from "@/layouts/Layout.astro";
import HorizonalList from '@/components/HorizontalList.astro';
import HorizonalListItem from '@/components/HorizontalListItem.astro';
---
<Layout>
  <SEOMeta 
    slot="head"
    title="Why RNA | Phaeno"
    description="RNA hold the keys to more fully understanding biology. Sequencing RNA is how we understand functional genes."
    documentType="Web Page"
  />  
  <main>
    <TopPageBanner title="Why RNA?" />
    <section>
      <p class="p-0 m-0">
        <a href="/#why-rna">Home</a>
        <span>&nbsp;&gt;&nbsp;</span>
        <a href="/what-went-wrong/#why-rna">What Went Wrong</a>
        <span>&nbsp;&gt;&nbsp;Why RNA?</span> 
      </p>
      <h2>Protein codes are found in the transcriptome, not genomic DNA.</h2>
      <p>
        The great conceptual leap required for precision medicine was recognizing that the full phenotypic potential of 
        the human genome is realized only after complex steps in RNA processing.  For each DNA gene, alternative RNA splicing, 
        RNA editing and other processes – create multiple products from every gene – most often with different molecular functions.        
      </p>
      <p>
        Messenger RNAs more closely correspond to our intuitive notion of a gene than the source DNA gene. mRNAs code
        individual protein isoforms, often with sophisticated variations in function – along with regulatory information
        governing the sites, timing and levels of expression.
      </p>
         
      <!-- <p>
        RNAs have multiple functionalities, including trafficking codes that specify where a protein will be made,
        ribozymes that can activate or inactivate the protein synthesis, 'riboswitches' that can regulate gene
        expression signaled by fluctuating levels of metabolites, cofactors, or inorganic ions, and RNA-specific
        activation and subsequent gene specific inactivation and RNA degradation.
      </p> -->

      <p>
        Almost unbelievably, variations in splicing of mRNAs of the subunites of macromolecular protein complexes 
        are developmentally regulated in concert – simultaneously, across all genes active in a cell and tissue.
      </p>

      <p>Only after RNA processing:</p>
      <HorizonalList columns={[1, 1, 2, 2]}>
        <HorizonalListItem>
          Does the structure emerge in which genetic mutations exert their effects.
        </HorizonalListItem>
        <HorizonalListItem>
          Can disease-causing isoforms the detected that result from abnormal RNA processing - in effect, mutations
          invisible in genome sequencing.
        </HorizonalListItem>
      </HorizonalList>

      <p>
        Only from whole-transcriptome sequencing can the full array of 2,500 -3,000 protein complexes of the normal or disease phenotype of each cell be glimpsed.
      </p>

      <BlockQuote
        text="What makes you and me individual human beings is not a unique set of DNA but instead a unique organization of cells and their activities."
        imageUrl="/images/arias.webp"
        imageAlt="Head shot of Alfonso Martinez Arias"
      >
        <b>Alfonso Martinez Arias</b><br/>Cambridge University<br /><i>The Master Builder: How the New Science of the Cell Is Rewriting the Story of Life</i>, 2023
      </BlockQuote>

      <h3>
        The tools needed to analyze the transcriptomes have arrived.
      </h3>
      <p>The computational, analytical tools, including machine learning and hardware, for charactering full transcriptomes are largely
        in hand. <b>Releasing their full power only awaits reliable transcriptome deep sequencing</b>.
      </p>
      <p>
        The full transcriptome has all of the information that determines both which proteins are expressed, and how all
        gene expression in the cell is regulated.
      </p>
      <p>
        While this information may be challenging to unravel, AI will almost certainly be able to discern diagnostic
        signatures for cancer and other complex diseases with high precision. It will also help identify optimal targets
        for small molecule drugs or advanced immune therapies.
      </p>
      <h3>
        Multi-omic information is largely captured in the transcriptome.
      </h3>
      <p>
        Multi-omics information, emerging from rapidly evolving technologies, largely converges to define the
        transcriptome and proteome.</p>
      <p>
        Essentially all the complex cellular processes, from epigenetic gene regulation, spatial genomics, 
        metabolomics – are both regulated by - and regulate - the expression of proteins. 
      </p>
      <h3>RNA facilitating proteomics for actionable information.</h3>
      <p>
        While the proteome is the goal, proteomic technology is not yet up to the challenge of visualizing global 
        expression throughout the cell and for all proteins.
      </p>
      <p>
        Only the full transcriptome surveys all potentially expressed protein isoforms, for all genes that are active in the cell.         
      </p>
      <p>
        This information can help focus proteomic technology in confirming the expression and post-transcriptional modifications of target 
        proteins important in explaining the molecular cause of disease or as targets for drugs or immune therapies.
      </p>
      <h2>Protein Isoform Examples from Oncology</h2>
      <p>
        Oncologists have been aware of the disconnect between genes and phenotype for a long time. 
        For example, there is a 10% to 25% discordance rate between 
        protein-based versus gene-based tests for HER2.
      </p>      
      <BlockQuote
        text="Discordance between protein expression and gene status is not uncommon and has significant therapeutic implications. A HER2 IHC score of 2+, for example, can either lead to targeted therapy or not, depending on a confirmatory FISH test. These discrepancies underscore the importance of using orthogonal testing strategies to accurately guide treatment."
        imageUrl="/images/reis-filho.webp"
        imageAlt="Head shot of Dr. Reis-Filho"
      >
        <b>Jorge S. Reis-Filho</b><br/>
        <span>Memorial Sloan Kettering Cancer Center</span><br/>
kn        <span><i>Breast Cancer Res</i>, 2005</span>
      </BlockQuote>
      
      <p>
        These discordances cannot be fully explained by inter-laboratory variability or methodological differences. In many cases, they reflect underlying biological 
        factors - for example, the expression of alternative HER2 protein isoforms such as p95HER2, which lack the extracellular domain targeted by standard IHC 
        antibodies and may therefore escape detection, despite underlying gene amplification.
      </p>

      <BlockQuote
        text="A subgroup of HER2‑overexpressing tumors also express p95HER2, an amino-terminally truncated receptor that lacks the extracellular domain but retains a highly functional HER2 kinase domain."
        imageUrl="/images/scaltriti.webp"
        imageAlt="Head shot of Dr. Scaltriti"
      >
        <b>Maurizio Scaltriti</b><br/>
        <span>Vall d'Hebron University Hospital and Research Institute, Barcelon, Spain</span><br/>
        <span><i>J. Natl Cancer Inst</i>, 2007</span>
      </BlockQuote>
      
      <p>What is true for HER2 is also true across virtually all cancer biomarkers.</p>
      <h4>Examples of protein isoform variances in other cancer biomarkers:</h3>
      <ul class="data-table">
        <li>
          <div class="data-item biomarker">Biomarker</div>
          <div class="data-item gene-test">Gene Test</div>
          <div class="data-item protein-test">Protein Test</div>
          <div class="data-item discordance">Isoform / Modification Discordance</div>
        </li>
        {biomarkers.map(item => (
          <li>
            <div class="data-item biomarker">{item.Biomarker}</div>
            <div class="data-item gene-test"><div class="data-label">Gene Test</div>{item.GeneTest}</div>
            <div class="data-item protein-test"><div class="data-label">Protein Test</div>{item.ProteinTest}</div>
            <div class="data-item discordance"><div class="data-label">Discordance</div>{item.Discordance}</div>
          </li>          
        ))}
      </ul>            
      <br/><br/>
      <div class="text-sm mt-2"><b>References for HER2:</b></div>
      
      <div class="text-xs mt-2"><b>HER2 Isoform Issue</b></div>
      <p class="text-xs mt-2">Scaltriti M, Rojo F, Ocana A, et al. <i>Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.</i> J Natl Cancer Inst. 2007;99(8):628-638. doi:10.1093/jnci/djk134</p>
      <p class="text-xs mt-2">Arribas J, Baselga J, Pedersen K, <i>Parra-Palau JL. p95HER2 and breast cancer.</i> Cancer Res. 2011;71(5):1515–1519. doi:10.1158/0008-5472.CAN-10-3795</p>
      
      <div class="text-xs mt-2"><b>Breast Cancer:</b></div>
      <p class="text-xs mt-2">Yin L, Zhang H, Liang X, et al. <i>Clinicopathological characteristics and biological markers of primary and recurrent or metastatic breast cancer: a meta-analysis.</i> Oncology Advances. 2024;4(1):e00027. doi:10.20801/ona.2024.00027</i></p>
      <p class="text-xs mt-2">Press MF, Sauter G, Bernstein L, et al. <i>Diagnostic evaluation of HER2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large prospective clinical trials.</i> Breast Cancer Res Treat. 2005;86(1):1-13. doi:10.1007/s10549-004-4561-3</p>

      <div class="text-xs mt-2"><b>Gastric/Gastroesophageal Cancer:</b></div>
      <p class="text-xs mt-2">Park SR, Park YS, Ryu MH, et al. <i>Extra-gastric metastases of HER2-positive gastric carcinoma: discordance of HER2 status between primary tumors and metastatic lesions.</i> Sci Rep. 2017;7:13023. doi:10.1038/s41598-017-03304-9</p>
      <p class="text-xs mt-2">Kim MA, Jung EJ, Lee HS, et al. <i>Prognostic significance of HER2 gene amplification and protein overexpression in gastric carcinoma: a study of 587 patients.</i> Int J Cancer. 2008;122(4):967-975. doi:10.1002/ijc.23187</p>
      <p class="text-xs mt-2">Lee HE, Park KU, Yoo SB, et al. <i>Clinical significance of intratumoral HER2 heterogeneity in gastric cancer.</i> Eur J Cancer. 2013;49(6):1448-1457. doi:10.1016/j.ejca.2012.10.019</p>
  
      <div class="text-xs mt-2"><b>Other Solid Tumors / Pan-Cancer Studies:</b></div>
      <p class="text-xs mt-2">Sahin IH, Lee C, Svrcek M, et al. <i>Discordance of HER2 expression and/or amplification between primary tumors and metastases in gastrointestinal malignancies.</i> Mol Cancer Ther. 2023;22(8):976–985. doi:10.1158/1535-7163.MCT-22-0966</p>

      <div class="text-sm mt-2"><b>References for Other Biomarkers:</b></div>
      <div class="text-xs mt-2"><b>EGFR:</b></div>
      <p class="text-xs mt-2">Sharma SV, Bell DW, Settleman J, Haber DA. <i>Epidermal growth factor receptor mutations in lung cancer.</i> Nat Rev Cancer. 2007;7(3):169–181.</p>
      <p class="text-xs mt-2">Wei J, et al. <i>Discordance between EGFR mutation status and EGFR protein expression in non-small cell lung cancer.</i> Oncology Letters. 2019;17(6): 5047–5052.</p>

      <div class="text-xs mt-2"><b>PD-L1:</b></div>
      <p class="text-xs mt-2">Ilie M, Long-Mira E, Bence C, et al. <i>Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients.</i> Ann Oncol. 2016;27(1):147–153.</p>
      <p class="text-xs mt-2">Wang Y, et al. <i>PD-L1 expression variability in lung cancer: causes and consequences.</i> Cancer Commun. 2020;40(2):87–98.</p>

      <div class="text-xs mt-2"><b>ER/PR:</b></div>
      <p class="text-xs mt-2">van de Vijver MJ, et al. <i>A gene-expression signature as a predictor of survival in breast cancer.</i> N Engl J Med. 2002;347(25):1999–2009.</p>
      <p class="text-xs mt-2">Shibata A, et al. <i>Discordance in ER, PR, and HER2 between primary breast cancer and brain metastases.</i> J Clin Oncol. 2018;36(suppl):1016.</p>

      <div class="text-xs mt-2"><b>ALK / ROS1 / NTRK:</b></div>
      <p class="text-xs mt-2">Camidge DR, Doebele RC. <i>Treating ALK-positive lung cancer — early successes and future challenges.</i> Nat Rev Clin Oncol. 2012;9(5):268–277.</p>
      <p class="text-xs mt-2">Solomon JP, Linkov I, Rosado A, et al. <i>NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls.</i> Mod Pathol. 2020;33:38–46.</p>

      <div class="text-xs mt-2"><b>TP53:</b></div>
      <p class="text-xs mt-2">Soussi T, Wiman KG. <i>TP53: an oncogene in disguise.</i> Cell Death Differ. 2015;22(8):1239–1249.</p>
      <p class="text-xs mt-2">Bártová E, et al. <i>p53-dependent mechanisms of gene regulation and chromatin remodeling.</i> Cell Mol Life Sci. 2019;76:2249–2261.</p>

      <div class="text-xs mt-2"><b>CD20:</b></div>
      <p class="text-xs mt-2">Tedder TF, Engel P. <i>CD20: a regulator of cell-cycle progression of B lymphocytes.</i> Immunol Today. 1994;15(9):450–454.</p>
      <p class="text-xs mt-2">Johnson NA, Boyle M, Bashashati A, et al. <i>Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival.</i> Blood. 2009;113(16):3773–3780.</p>
    </section>
  </main>
</Layout>

<style lang="scss">
ul {
  margin: 0;
  padding: 0;
  gap: 0;
  li {
    display: flex;
    font-size: .75rem;
    
    div.data-item {
      border-right: 1px solid rgb(179, 179, 179);
    }
    div.data-item:last-of-type {
      border-right: none;
    }    

    &:nth-child(even) {
      background-color: rgba(183, 204, 183, 0.589);
    }  
    &:nth-child(odd) {
      background-color: rgb(241, 241, 226);
    }    
    &:first-child {
      font-size: .9rem;
      font-weight: bold;
      background-color: rgb(201, 201, 201);
      border-bottom: 1px solid rgb(202, 202, 202);
    }
  }

  .data-item {
    display: flex;
    padding: 5px;
  }
  
  .label {
    display: none;
   }

  @media (max-width: 725px) {
    li {
      display: block;
      padding: 7px;

      div.data-item {
        border-right: none;
        padding: 0;
      }  
      
      &:first-child {
        display: none;
      }

      > div:first-of-type {
        font-weight: bold;
        font-size: .925rem;
      }

    }
  }
}

.data-item {
  display: flex;
  padding: 0 7px;
  overflow-wrap: break-word;
  word-break: break-word;
}

.data-label {
  display: none;
  font-weight: bolder;
}

.biomarker {
  width: 10rem;
}

.gene-test {
  width: calc((100% - 10rem) / 3);
}

.protein-test {
  width: calc((100% - 10rem) / 3);
}

.discordance {
  width: calc((100% - 10rem) / 3);
}

@media (max-width: 725px) {  
  .gene-test,
  .biomarker, 
  .protein-test,
  .discordance,
  .data-item {
    width: 100%;
    display: block;
  }

  .data-label {
    display: block;
    font-style: italic;
    width: 6rem;
    flex-shrink: 0;
  }

  .data-label::after {
    content: ": ";
    white-space: pre; /* or pre-line */
  }  

}
</style>